Explore RAD-140 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
RAD-140 (testolone) is an oral SARM — a small molecule, not a peptide — sourced in research for muscle and breast-cancer studies. It is sold as a research chemical (capsules or an oral liquid), not an approved drug.
RAD-140 binds androgen receptors with reported tissue selectivity favouring muscle and bone over prostate and other reproductive tissue, with the design intent of producing the anabolic effects of testosterone without the same dose-limiting androgenic and prostate effects.[3] The tissue-selectivity premise rests on pre-clinical work in rodents and primates; clinical-trial data in humans for body-composition endpoints does not exist. In the breast-cancer program, the mechanism leveraged is the antagonist effect at androgen receptors over-expressed in some hormone-receptor-positive breast tumours, not the muscle-bone agonism that drives consumer interest.
The Radius Phase 1 trial in heavily pre-treated hormone-receptor-positive breast cancer was the only registered human RAD-140 study and was terminated by the sponsor.[4] No Phase 2 or Phase 3 trial of RAD-140 has been completed for any indication. The published case-report literature, however, has accumulated a concerning cluster of drug-induced liver injury (DILI) reports in healthy young men using RAD-140 obtained from the research-chemical market — including severe cholestatic hepatitis requiring hospitalisation and persistent transaminase elevation.[5][6][7]
Not FDA-approved for any indication; no Phase 2/3 data. FDA 2017 warning letter against marketing SARMs to consumers. WADA-prohibited at all times. Research-grade material only.
RAD-140 has a reported half-life of ~20 hours (estimated). The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. A roughly day-long half-life means once-daily dosing keeps levels fairly steady, with modest buildup over the first few days. Human PK data are limited. Pharmacokinetic source: Limited phase 1 / pre-clinical data (testolone). It is catalogued under Other Peptides on WPA.
7 RAD-140 reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.